Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in TEM.

← Back to Free Index

TEM

Analysis as of: 2026-06-21

Tempus AI, Inc.

Tempus AI sells molecular diagnostics, de-identified multimodal data and analytics, and clinical workflow software to oncologists, health systems, and biopharma companies.

ai biotech healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Closed-Loop Precision Medicine, Pending Economic Proof

The upside case is credible because the company already has real diagnostics scale, real data assets, and growing workflow surfaces. The debate is whether those assets mature into higher-margin recurring utility revenue fast enough to justify a sustained premium multiple.

Analysis

Thesis

Tempus can compound by turning each diagnostic interaction into a data, evidence, and workflow asset; if it shifts mix from reimbursed testing toward higher-value recurring data and operating-system revenue, the business can outgrow standard diagnostics and earn a better multiple by 2031.

Last Economy Alignment

Cheaper cognition makes Tempus’ proprietary data, regulated assays, and embedded workflows more valuable; the limiter is external proof, reimbursement, and privacy permissioning rather than AI seat commoditization.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.5x (from 5 most recent analyses)

Reasoning

This is a real-business compounding story, not a pure AI rerating story. Diagnostics should keep growing and refreshing the dataset, but the equity upside depends on Data and Applications, evidence products, and workflow surfaces becoming a bigger share of revenue. If that happens, Tempus should trade above classic diagnostics peers but still below pure software, which supports a strong multiyear outcome without requiring a heroic 10x scenario.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is economic conversion, not product existence. Tempus has real demand, real data assets, and credible product breadth, but durable upside still passes through reimbursement, FDA cadence, privacy permissioning, and workflow ownership. If MRD stays margin-dilutive or customers keep Tempus as a useful supplier rather than a trusted operating layer, revenue can grow while the multiple stays capped.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

A June 11 validation update broadened Tempus’ cardiology credibility, but it does not yet change the 2031 earnings model.
No new guidance, financing, or reimbursement disclosure appeared in the last 7-10 days, so the setup is still anchored to Q1 results and the late-May launch cluster.
The regulatory focus has shifted from waiting on the tumor-only xT decision to executing migration and proving that the 2027 pricing benefit is real.

Thesis update

No material change. One regulatory gate improved, but the core thesis still depends on converting better product breadth into higher-quality recurring revenue.

Forecast update

Regulatory de-risking improved confidence, but the higher starting valuation and unresolved reimbursement gates offset most of that benefit.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.56

They control hard-to-copy medical data, regulated tests, and points inside clinician workflow, so cheaper AI makes their system more useful instead of replacing it. The risk is that reimbursement rules, privacy limits, or EHR owners keep them as a supplier rather than the trusted operating layer.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$66.53

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research